Business
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects of chemotherapyAMPLICITY Trial Initiation: The Phase 1b/2a AMPLICITY trial has started, combining narmafotinib with FOLFIRINOX chemotherapy, aiming to determine the optimal daily dose. Patient recruitment is ongoing i
About this update from Amplia Therapeutics Ltd.
[{"type":"text","content":"Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter","length":87,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects of chemotherapy","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"AMPLICITY Trial Initiation: The Phase 1b/2a AMPLICITY trial has started, combining narmafotinib with FOLFIRINOX chemotherapy, aiming to determine the optimal daily dose. Patient recruitment is ongoing in Melbourne and Sydney with US sites planned to open imminently","length":265,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory and Commercial Developments: Positive FDA feedback on dose optimization was received; a key patent for narmafotinib was granted; and Amplia successfully uplisted to the US-based OTCQB Venture Market, enhancing its investor reach","length":239,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical Studies: The second phase of a research program evaluating the activity of narmafotinib in patient-derived pancreatic cancer cells carrying specific genetic mutations has been initiated","length":197,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":911,"olType":false},{"type":"text","content":"Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX; OTCQB: INNMF), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is announces further clinical and preclinical progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 31 December 2025.","length":415,"tagName":"p"},{"type":"text","content":"Operations Update","length":17,"tagName":"p"},{"type":"text","content":"Amplia continues to progress the clinical development of narmafotinib, the Company’s best-in-class FAK inhibitor, for the treatment of metastatic pancreatic cancer in two clinical trials. This quarter the Company has reported updated results from the ACCENT trial, as well as important progress in regulatory interactions, intellectual property, investor outreach and preclinical studies.","length":388,"tagName":"p"},{"t...